For Health Professionals

Switch to mobile view »

Urocit®-K inhibits stone formation with a broad range of efficacy

Urocit®-K is indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.

Urocit®-K is effective in:
Metabolic Cause Stone Composition
hypocitraturia calcium oxalate
hyperuricosuria calcium oxalate
idiopathic uric acid nephrolithiasis uric acid
hypercalciuria calcium oxalate
undue urinary acidity uric acid
renal tubular acidosis calcium oxalate
Table 1

Urocit®-K increases urinary citrate and urinary pH1-3

Urocit®-K alkalinizes the urine. The citrate moiety, which is largely oxidized, is absorbed while the K ion remains, leaving an alkali load. The alkali load increases urinary citrate (inhibiting crystallization) and urinary pH (contributing to retardation of crystallization of calcium salts and inhibition of uric acid crystallization). Urocit®-K decreases urinary saturation of calcium oxalate and inhibits both calcium oxalate and its crystallization.

Urocit®-K inhibits stone formation in more than 90% of patients3,7,8

Urocit®-K produces remission (cessation of stone formation) in over 70% of patients.3,7,8

  Renal Tubular Acidosis Chronic Diarrheal Syndrome Idiopathic Hypocitraturia Uric Acid Stones
Pre-Treatment
Duration (yr/pt)
3 3 3 3
Stone Formation
Rate (no./yr)
39.3 4.69 2.11 1.20
Treatment
Duration (yr/pt)
2.83 3.2 2.13 2.78
Stone Formation
Rate (no./yr)
0* 0.71* 0.28* 0.01*
Remission (%) 100 70 89 94
Reduced Stone
Formation
Rate (%)
100 90 100 100

Urocit®-K is contraindicated in patients with hyperkalemia and/or renal insufficiency.

* p<0.01

Table 2

Important Safety Information

Contraindications

  • Patients with hyperkalemia, peptic ulcer disease, active urinary tract infection, and renal insufficiency
  • Conditions predisposing patients to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown

Warnings and Precautions

  • Hyperkalemia: In patients with impaired mechanisms for excreting potassium, Urocit-K administration can produce hyperkalemia and cardiac arrest. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of Urocit-K in patients with chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure, should be avoided
  • Gastrointestinal lesions: If there is severe vomiting, abdominal pain or gastrointestinal bleeding, Urocit-K should be discontinued immediately and the possibility of bowel perforation or obstruction investigated

Patient Counseling Information

Administration of Drug
  • Patients should be told to take Urocit-K 15 mEq without crushing, chewing, or sucking the tablet
  • Patients should be told to take Urocit-K 15 mEq only as directed, especially if the patient is also taking both diuretics and digitalis preparations
  • Patients should be told to check with the doctor if they experience difficulty swallowing the tablet or it seems to stick in the throat
  • Patients should be told to check with the doctor at once if they notice tarry stools or other signs of gastrointestinal bleeding
  • Patients should be advised that regular blood tests and electrocardiograms will be performed to ensure safety

Patient Monitoring Information

Hyperkalemia

  • Patients with impaired mechanisms for excreting potassium should be closely monitored for signs of hyperkalemia with periodic blood tests and ECGs

This material is intended to provide basic information. Patients should discuss all medical advice, diagnosis, and treatment with their healthcare provider.

Please see full Prescribing Information


Click here to save up to 480 dollars on 12 prescriptions

StoneDisease.org

Information about the causes, symptoms, diagnosis, and treatment of stone disease Website»

Thiola® (tiopronin)

For the prevention of cystine kidney stone formation
Website»

Lithostat® (acetohydroxamic acid)

Adjunctive therapy in patients with chronic urea-splitting urinary infection
Website»

Share on FacebookShare on MySpaceShare on TwitterShare on DiggShare on Yahoo! BuzzShare on StumbleUponShare on redditShare on TechnoratiShare on del.icio.usShare on LinkedIn